

Belgian guidelines for the treatment of non-infectious uveitis (NIU)

Panel:

Prof. Dr. Laure Caspers, Dept. of Ophthalmology, CHU Saint Pierre, ULB, Brussels

Dr. Ilse De Schryver, Dept. of Ophthalmology, University Hospitals Gent

Dr. Nacima Kisma, Dept. of Ophthalmology, Erasmus Hospital, ULB, Brussels

Dr. Alexandra Kozyreff, Dept. of Ophthalmology, Cliniques Universitaires St-Luc UCL, Brussels

Dr. Joachim Van Calster, Dept. of Ophthalmology, University Hospitals Leuven

Prof. Dr. François Willermain, Dept. of Ophthalmology, CHU Saint Pierre and CHU Brugmann, ULB, Brussels

General considerations:

1. Topical treatment in anterior uveitis and as adjuvant treatment in intermediate/posterior uveitis and panuveitis
2. Parabalbar/intravitreal injections in intermediate/posterior uveitis and panuveitis and as adjuvant treatment in anterior uveitis.
3. Systemic (oral, intravenous) treatment in bilateral moderate or severe or severe unilateral intermediate/posterior uveitis or panuveitis. Systemic treatment only indicated in very selected cases of anterior noninfectious uveitis.
4. The use of systemic steroids and other immunomodulatory agents is associated with various side effects, some of them being very severe and potentially fatal. A multidisciplinary approach is recommended. In every case, patients should be correctly informed.

Systemic treatment:

1. Corticosteroids continue to have a vital role in the acute phase of NIU, but their use as a maintenance therapy is limited by their associated side effects. The American Uveitis Society expert consensus recommendations suggest a maintenance dose of ≤ 7.5 mg if possible and no more than 10 mg oral prednisolone equivalent per day, and this is broadly in line with guidelines from other inflammatory diseases.
2. The oral corticosteroids loading dose is usually 1 mg/kg/day with a minimum of 0.5mg/kg/day. Tapering of long standing treatment has to be executed for at least 12 weeks. Depending on inflammation severity and the presence of sight

threatening lesions, starting with an intravenous treatment may be necessary in the acute stage of severe sight threatening uveitis.

3. In uveitis not responding to corticosteroids, or when there is a need for corticosteroid sparing treatment in patients unable to reduce oral prednisolone under 8 mg daily, an immunosuppressive agent alone or in combination with low doses of oral prednisolone ≤ 7.5 mg daily) is indicated.

Inadequate response can be defined by worsening of one or more of the following criteria:

- ✓ Active chorioretinal or retinal vascular lesions OK
- ✓ Anterior chamber cells OK
- ✓ Vitreous haze OK
- ✓ (Macular edema: considered now as a complication of uveitis)
- ✓ (Best corrected visual acuity (BCVA): can be due to cataract of glaucoma)

4. Addition of immunosuppressive/immunomodulatory agents might also be proposed in patients with a good steroid response but who developed unacceptable side effects.

5. Suggested immunosuppressive/ immunomodulatory medication:

- ✓ Methotrexate (MTX): starting dose of 7.5-12.5mg/week, to titrate to a maximal dosage of 20-(25) mg/w following systemic toxicity and clinical response. Treatment for at least 3 months.
 - Lag time of 4–6 weeks from initiation of treatment to full therapeutic effect.
 - Side effects include gastrointestinal symptoms, cytopenia, and hepatotoxicity; lung fibrosis.
- ✓ Azathioprine (AZA): starting dose of 2–3 mg/kg/day, titrated according to response and side effects. Treatment for at least 6 weeks.
 - Genotype screening for TPMT (thiopurine methyltransferase) deficiency is recommended before starting azathioprine to avoid important drug toxicity.
 - Efficacy is achieved within 4–12 weeks after commencing treatment.
 - Side effects include gastrointestinal upset and myelosuppression for which regular monitoring of blood count and liver enzymes is required.
- ✓ Mycophenolate mofetil (MMF): starting dose of 500 mg twice daily, increased to 1 g twice daily after 2 weeks provided that side effects are acceptable. Treatment for at least 6 weeks.

- Efficacy is achieved within 2–12 weeks after commencing treatment.
- Side effects include gastrointestinal disturbance, elevation of liver enzymes, leukopenia and thrombocytopenia.
- ✓ Cyclosporine (CSA): 2.5– 3 mg/kg daily (max 5 mg)/kg daily for at least 4 weeks. Needs to be tapered slowly to avoid rebound of the uveitis.
 - Fast acting, reaching peak efficacy within 7–15 days of initiation of therapy.
 - Side effects include hypertension, renal impairment, gingivitis, and hirsutism.

6. In patients with an inadequate response to one immunosuppressive/immunomodulatory treatment, or in which this treatment is inappropriate, a combination of two immunomodulatory agents with or without low doses of oral prednisolone (≤ 7.5 mg daily) can be an option. In such patients, biological medicines such as TNF-alfa blocking agents can be indicated either as a unique immunomodulatory therapy or in combination with a classical drug (usually, prednisolone, MTX , AZA or MMF).

Indications for primary combination therapy (corticosteroids + add-on):

1. Absolute indications for primary immunomodulatory therapy following the American Academy of Ophthalmology (AAO):

- ✓ Behçet's disease
- ✓ Juvenile idiopathic arthritis
- ✓ VKH/sympathetic ophthalmia
- ✓ Serpiginous choroiditis
- ✓ Wegener granulomatosis

2. Indication for primary biological therapy:

- ✓ Behçet's disease

References:

1. Therapies in Development for Non-Infectious Uveitis. Sadiq MA, Agarwal A, Hassan M, Afridi R, Sarwar S, Soliman MK, Do DV, Nguyen QD. *Curr Mol Med*. 2015;15(6):565-77.
2. Pharmacotherapy for uveitis: current management and emerging therapy. Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. *Clin Ophthalmol*. 2014 Sep 22;8:1891-911. doi: 10.2147/OPTH.S47778. eCollection 2014.
3. Emerging therapies for noninfectious uveitis: what may be coming to the clinics. Maya JR, Sadiq MA, Zapata LJ, Hanout M, Sarwar S, Rajagopalan N, Guinn KE, Sepah YJ, Nguyen QD. *J Ophthalmol*. 2014;2014:310329. doi: 10.1155/2014/310329. Epub 2014 Apr 24.
4. The future of uveitis treatment. Lin P, Suhler EB, Rosenbaum JT. *Ophthalmology*. 2014 Jan;121(1):365-76. doi: 10.1016/j.ophtha.2013.08.029. Epub 2013 Oct 26.
5. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Lee RW, Dick AD. *Eye (Lond)*. 2012 Jan;26(1):17-28. doi: 10.1038/eye.2011.255. Epub 2011 Sep 30.
6. Emerging drugs for uveitis. Larson T, Nussenblatt RB, Sen HN. *Expert Opin Emerg Drugs*. 2011 Jun;16(2):309-22. doi: 10.1517/14728214.2011.537824. Epub 2011 Jan.
7. New developments in corticosteroid therapy for uveitis. Taylor SR, Isa H, Joshi L, Lightman S. *Ophthalmologica*. 2010;224 Suppl 1:46-53. doi: 10.1159/000318021. Epub 2010 Aug 18.
8. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kumar Kurup S, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP. *The Lancet*. Published online August 16, 2016 [http://dx.doi.org/10.1016/S0140-6736\(16\)31339-3](http://dx.doi.org/10.1016/S0140-6736(16)31339-3) 1
9. Adalimumab in Patients with Active Noninfectious Uveitis. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. *N Engl J Med*. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852.
10. Adalimumab in the Treatment of Uveitis in Juvenile Idiopathic Arthritis. Thorne JE. *N Engl J Med*. 2017 Apr 27;376(17):1682-1683. doi: 10.1056/NEJMe1701811.
11. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group. *N Engl J Med*. 2017 Apr 27;376(17):1637-1646. doi: 10.1056/NEJMoa1614160.